| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3c3ff46221600d8162d39f5357778a4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_58b1470680855aa8a1da114c7caba3e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_673bd6ff1c13f950b71375eb9cee1d6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90bfd30de2b76313e15b131b1b2bb441
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f44c0958fc92d2e572300aba9f1d0cd3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5252
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18171
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18163 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| filingDate |
2011-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26489c4bc2d719b58e42e1add2d8e80b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d42960c0b5a5d054f6a719ac45dfb2d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7817013110760ccf646dab91c797ceaa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38c4f3b7232495a5856716a646796e94 |
| publicationDate |
2012-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012067483-A2 |
| titleOfInvention |
Newcastle disease virus and the use thereof as a vaccine |
| abstract |
The present invention relates to new Newcastle viruses of any genotype and new fragments of the genome of the Newcastle disease virus that encode for the F and HN proteins - constructed through reverse genetics and recombination - of high antigenicity for the preparation of vaccines for the prevention of Newcastle disease by reducing viral excretion or for the use thereof as vectors with other viruses in a lyophilized form or emulsified in oil. Likewise, it can be used as a vector in combination with other pathogenic agents. |
| priorityDate |
2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |